Royalty Table

Royalties from other partnered products not listed are either single or double digit royalties as described under collaborative research and development programs in the current 10-K. Not all royalties are disclosed due to confidentiality requirements.

 

 

Eltrombopag (PROMACTA®)(1)(2)                    
4.7% 
6.6% 
7.5% 
9.4% 
9.3%
Less than $100M annual sales
Sales in range of $100M - $200M 
Sales in range of $200M - $400M 
Sales greater than $400M 
Sales greater than $1.5B
GSK-5921(2) 14.5%All sales (6.5% for first year sales)
Carfilzomib (KYPROLIS®)(1)Onyx

1.5% 
2.0% 
2.5% 
3.0%

Sales up to and including $250M 
Sales in range of $251M - $500M 
Sales in range of $501M - $750M 
Sales greater than $750M

AVINZA® (1) 5%If sales are less than $200M annually 
Higher royalties paid if sales exceed $200M
Bazedoxifene (VIVIANT™)(1)
BZA/CE (DUAVEE™)


 0.5% 
1.5% 
2.5%
Less than $400M annual sales 
Sales in range of $400M - $1.0B annually 
Sales greater than $1B annually 
Sparsentan Retrophin9%All sales

 

(1)

 Currently receiving royalty payments

(2)

 Net of payments due to The Rockefeller University.